Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prognosis in Guillain-Barre Syndrome
NCT06041451Phase 4Unknown
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Jan 2013
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of intravenous immunoglobulin G and methylprednisolone injection in Guillain-Barré syndrome (GBS) (4 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: severity of Guillain-barre syndrome at 26 weeks. Status: unknown.
02
Drugs
intravenous immunoglobulin Gmethylprednisolone injection
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT06041451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041451.